Daclizumab: profile and news

PDL's Potent Pick-Me-Up Feb 27, 2006
R&D portfolio. In 2004 and 2005, PDL consummated R&D collaborations with Roche Holdings for the development of daclizumab. A development ... - BusinessWeek

PDL BioPharma Announces Fourth Quarter and Full Year 2005 ... Feb 27, 2006
The increase reflected expanded clinical trial efforts for Nuvion®, ularitide and daclizumab, manufacturing-related costs and additional personnel in these ... - Yahoo! News (press release)

PDL BioPharma Set For Years Of Growth Feb 24, 2006
...through 2009," wrote the analyst, adding that PDL and Biogen Idec (nasdaq: BIIB - news - people ) are planning to jointly develop daclizumab, a treatment of ... - Forbes

Tysabri Events For Biogen Idec Overshadow Year-End Figures Feb 17, 2006
28. Also in the pipeline, Biogen Idec has oral fumarate BG-12 in Phase II development for multiple sclerosis; daclizumab, for the same indication, which is ... - BioWorld Online (subscription),

Other information

Indication
For prevention of renal transplant rejection

Pharmacology
Zenapax functions as an IL-2 receptor antagonist. Specifically it inhibits IL-2-mediated activation of lymphocytes, a critical pathway in the cellular immune response involved in allograft rejection.

Mechanism Of Action
Zenepax binds with high-affinity to the Tac subunit of the high-affinity IL-2 receptor complex and inhibits IL-2 binding. The IL-2 receptor (Tac) subunit is expressed on activated but not resting lymphocytes.

Drug Category
Immunosupressants; Immunomodulatory Agents; unclassified therapeutic agents (92:00.00)

Brand Names/Synonyms
Ig gamma-1 chain C region; humanized antiCD25; anti-IL-2; Zenapax (Hoffmann-La Roche Inc)

Dosage Forms
LIQUID

Absorption
Not Available

Interactions
Not Available

Chemical IUPAC Name
Humanized anti-CD25 antibody

Chemical Formula
C6332H9808N1678O1989S42 >Humanized Anti-CD25 Light Chain 1 >Humanized Anti-CD25 Heavy Chain 2 >Humanized Anti-CD25 Light Chain 2

Half Life
11-38 days

Drug Type
Approved Drug

# Accession No
BIOD00007

CAS Registry Number
152923-56-3